Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 24, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - April 24, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/24/17 - "Pharmaceutical Compositions of Spiro-Oxindole Compound for Topical Administration and Their Use as Therapeutic Agents" in Patent Application...
"Pharmaceutical Compositions of Spiro-Oxindole Compound for Topical Administration and Their Use as Therapeutic Agents" in Patent Application Approval Process. By a News Reporter-Staff News Editor at AIDS Weekly A patent application by the inventors Winters, Conrad Stewart; Yang, Meidong; Chen, Haigang, filed on October 11, 2016, was made availab
4/24/17 - Acasti Granted Additional Composition & Use Patents in Taiwan and Australia; Safeguards Valuable Market Expansion Opportunities
Acasti Pharma Inc., a biopharmaceutical innovator focused on the research, development and commercialization of CaPre for the treatment of severe hypertriglyceridemia, today announced the granting of additional patents by the Taiwanese and Australian patent offices, further expanding the intellectual property position of CaPre.
4/24/17 - Acelrx Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Apr. 11, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acelrx Pharmaceuticals Inc. was posted on April 11, 2017. The SEC file number is 0001437749-17-006460.. A U.S. Securities and Exchange Commission fil
4/24/17 - Acerus to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference
Acerus Pharmaceuticals Corporation announced today that Tom Rossi, President and Chief Executive Officer of Acerus, is scheduled to present an overview of the company at the sixth annual Bloom Burton& Co. Healthcare Investor Conference. Rossi s address will take place at the Sheraton Centre Toronto Hotel on May 2, 2017 at 4:00 p.m. Eastern Time.
4/24/17 - Achaogen Unveils Data Highlighting the Effectiveness of Plazomicin Against MDR Gram-Negative Bacteria at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Achaogen, Inc., a late-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant gram-negative infections, today announced multiple presentations that highlight the effectiveness of plazomicin against MDR gram-negative bacteria in multiple settings. Gram-negative infections with resistance to...
4/24/17 - Aclaris Therapeutics Hosts Symposium on JAK Inhibitors at the 76th Annual Society for Investigative Dermatology Meeting
Aclaris Therapeutics, Inc., a dermatologist-led biotechnology company focused on defining new standards of care in medical and aesthetic dermatology, today announced it will sponsor a symposium on Janus Kinase inhibitors at the 76 th Annual Society for Investigative Dermatology Meeting in Portland, Oregon. Clinical investigation of JAK inhibitor.
4/24/17 - ACORDA NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics Inc. To Contact The Firm
By a News Reporter-Staff News Editor at Pharma Business Week- Faruqi& Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Acorda Therapeutics Inc.. District Judge Leonard Stark of the United States District Court for the District of Delaware invalidated the Company's four patents under U.S. Patent N
4/24/17 - Acorda Therapeutics Inc. Files SEC Form 8-K, Current Report (Apr. 6, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acorda Therapeutics Inc. was posted on April 6, 2017. The SEC file number is 0001564590-17-006156.. A U.S. Securities and Exchange Commission filing
4/24/17 - Adamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinson's Disease
Adamas Pharmaceuticals, Inc. today announced the presentation of two separate analyses of pooled data from the placebo-controlled Phase 3 clinical trials of ADS-5102 extended-release capsules in oral platform and poster presentation sessions at the 69 th American Academy of Neurology Annual Meeting in Boston. Adamas is excited to present this.
4/24/17 - Addivant? Receives Formal Approval from the FDA for Use of Its Nonylphenol-Free Antioxidant WESTON 705 in Infant Food and Breast Milk Plastic Packaging
Addivant?, the world leading supplier of liquid phosphite antioxidants for plastics, announced today that its nonylphenol-free stabilizer, WESTON 705, has received formal approval from the US Food and Drug Administration for use in infant formula and human milk plastic packaging. This approval from the FDA for use in infant formula and human m
4/24/17 - Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced that its Chairman and Chief Executive Officer, Doug Janzen, will present at the sixth annual Bloom Burton& Co. Healthcare Investor Conference on Monday May 1 st, 2017 at 3:00pm Eastern Daylight
4/24/17 - Agile Therapeutics Inc. Files SEC Form 8-K, Current Report (Apr. 11, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Agile Therapeutics Inc. was posted on April 11, 2017. The SEC file number is 0001104659-17-022892.. A U.S. Securities and Exchange Commission filing
4/24/17 - Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and in Additional Clinical Targets
Akari Therapeutics, an emerging growth, clinical-stage biopharmaceutical company, announced that it will present data from an interim analysis of its ongoing Phase 2 trial of Coversin in paroxysmal nocturnal hemoglobinuria, as well as preclinical data for additional indications and other opportunities, at today s Research and Development Day.
4/24/17 - Alder BioPharmaceuticals Presents Additional Data from Eptinezumab Development Program at 69th Annual American Academy of Neurology Meeting
Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today presented additional data for eptinezumab, which is in Phase 3 clinical development for the prevention of migraine, at the 69 th Annual American Academy of Neurology meeting in Boston. "The data presented today at the AAN
4/24/17 - Allergan Receives 2017 ENERGY STAR Partner of the Year - Sustained Excellence Award from U.S. Environmental Protection Agency
By a News Reporter-Staff News Editor at Pharma Business Week- Allergan plc announced that it has been named a 2017 ENERGY STAR Partner of the Year- Sustained Excellence Award winner. Allergan will be recognized by the U.S. Environmental Protection Agency and the U.S. Department of Energy in Washington, D.C. on April 26, 2017. Allergan has been an
4/24/17 - Allergan's Trademark Application for "CRINONE" Filed
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "CRINONE" by Susan J. Hinchey, representing Allergan. This application was made available to the public on April 11, 2017. The owner/registrar information for
4/24/17 - Allergan's Trademark Application for "VENTRU" Filed
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "VENTRU" by Susan J. Hinchey, representing Allergan. This application was made available to the public on April 06, 2017. The owner/registrar information for t
4/24/17 - Amag Pharmaceuticals Inc. Files SEC Form 8-A12B, Registration of Securities [Section 12(B)] (Apr. 10, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Amag Pharmaceuticals Inc. was posted on April 10, 2017. The SEC file number is 0001104659-17-022377.. A U.S. Securities and Exchange Commission filin
4/24/17 - Amag Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Apr. 10, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Amag Pharmaceuticals Inc. was posted on April 10, 2017. The SEC file number is 0001104659-17-022374.. A U.S. Securities and Exchange Commission filin
4/24/17 - Amag Pharmaceuticals Inc. Files SEC Form PRE 14A, Other Preliminary Proxy Statements (Apr. 10, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Amag Pharmaceuticals Inc. was posted on April 10, 2017. The SEC file number is 0000792977-17-000011.. A U.S. Securities and Exchange Commission filin
4/24/17 - American Regent Announces Enrollment of First Patient in Phase 3 Trial to Investigate Injectafer (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency
American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3 clinical trial, HEART-FID. "Iron deficiency affects up to half of all heart failure patients and is associated with impaired exercise tolerance, and mortality in patients with or without anemia, 2" said Adrian F. Hernandez,
4/24/17 - AmpliPhi Biosciences Review of Recent FDA Feedback and Drug Pipeline
NEW YORK, NY/ ACCESSWIRE/ April 24, 2017/ Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap public companies is issuing a comprehensive report with no obligation on AmpliPhi Biosciences Corporation, a biopharmaceutical company engaged in the discovery, development, and commercializat
4/24/17 - An Application for the Trademark "CREZINTA" Has Been Filed by Eli Lilly
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "CREZINTA" by Bruce W. Longbottom, representing Eli Lilly. This application was made available to the public on April 12, 2017. The owner/registrar information
4/24/17 - An Application for the Trademark "FROM THE COUGH EXPERTS" Has Been Filed by Pfizer
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "FROM THE COUGH EXPERTS" by Michele A. Farber, representing Pfizer. The owner/registrar information for this application is: Michele A. Farber, Pfizer, 235 Eas
4/24/17 - An Application for the Trademark "GASTROFLOATS" Has Been Filed by Sun Pharmaceutical Industries
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "GASTROFLOATS" by Craig Kuchii, Esq., representing Sun Pharmaceutical Industries. The owner/registrar information for this application is: Craig Kuchii, Esq.,
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415